Saturday 17 October 2026 Export ATHE’s income statement to Excel — free account

Alterity Therapeutics Limited - Sponsored ADR

ATHE Healthcare Biotechnology

Revenue growth for five consecutive years; insiders bought in the last twelve months.

2.62 0.10 −3.68%

Follow ATHE

Alert me

Market cap: $52.0M
P/E: 0.0×
Fwd P/E: —
Dividend yield: —
F-score: 4/9
Altman Z: 2.15
Beneish M: 30.19
Dividend safety: n/a

Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

Total buys 0.02

Totals in millions of $.

	Dec 25			Mar 26			Jun 26			Sep 26
Buy	—	—	—	—	—	—	—	—	—	1	—	—
Sell	—	—	—	—	—	—	—	—	—	—	—	—

Insider Ownership 67.99%

Capital & Financial Ratios $m

Market Cap 51.95

Revenue —

Net Income (34.76)

Free Cash Flow (35.13)

Net Debt (25.33)

Current Ratio 14.52

Debt/Equity 0.00

P/E ratio 0.00

Fwd P/E —

P/S ratio 0.00

P/B ratio 0.00

Past 5Y EPS Growth —

This Y EPS Growth (225.68%)

Next Y EPS Growth (30.09%)

Next Y revenue growth —

Next 5Y EPS Growth 24.85%

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/FCF against its own 10 years 48.99%

10-year low 10-year high

Dividends

Payout Ratio —

Annual Dividend Rate —

Annual Dividend Yield —

Assets vs Liabilities $m

	2023	2024	2025	2026
Cash	11	8	21	25
Receivables	6	3	3	5
Inventory	—	—	—	—
Other	2	2	6	1
	18	12	30	31

	2023	2024	2025	2026
Payables	2	3	2	1
ST’ Debt	—	—	—	—
Other	0	0	1	1
	3	4	2	2

Compound Annual Growth %

	10y	5y	3y
Sales	36.49%	(1.15%)	9.29%
Cash Flow	0.00%	0.00%	0.00%
Earnings	0.00%	0.00%	0.00%
Book Value	2.41%	4.96%	23.60%

Revenue $m

	Mar	Jun	Sep	Dec	Year
’26	—	—	—	—	—
’21	—	—	—	—	3
’20	—	—	—	—	0
’19	—	—	—	—	4
’18	—	—	—	—	3
’17	—	—	—	—	2

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	—	—	—	—	—
’26	—	—	—	—	(15)
’25	—	—	—	—	(7)
’24	—	—	—	—	(8)
’23	—	—	—	—	(13)
’22	—	—	—	—	(9)
’21	—	—	—	—	(13)

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	—	—	—	—	—
’26	—	(15)	—	(7)	(15)
’25	—	(7)	—	(5)	(7)
’24	—	(8)	—	(3)	(8)
’23	—	(13)	—	(7)	(13)
’22	—	(9)	—	(6)	(9)
’21	—	(13)	—	5	(13)

Fiscal quarters ending in the months shown.

EPS $

	Mar	Jun	Sep	Dec	Year
’26	—	—	—	—	—
’26	—	—	—	—	(0.91)
’25	—	—	—	—	(0.74)
’24	—	—	—	—	(2.06)
’23	—	—	—	—	(2.30)
’22	—	—	—	—	(2.32)
’21	—	—	—	—	(4.04)

Fiscal quarters ending in the months shown.

Group	Line	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026	2027e
Price, $
Price, $	Low	16.50	10.90	7.80	2.80	6.80	2.90	1.55	1.00	2.52	2.35	Analyst estimates 2027–2029 Powerpack
	High	45.80	32.80	27.20	51.50	27.50	12.30	5.41	3.88	7.00	5.89
People
People	Employees	9	14	14	12	11	12	12	10	9	9
	Revenue/emp, $m	0.26	0.18	0.26	0.01	0.31	0.00	0.00	0.00	0.00	0.00
Income, $m
Income, $m	Revenue	2	3	4	0	3	—	—	—	—	—
	Gross margin, %	100.00	100.00	100.00	100.00	100.00	0.00	0.00	—	—	—
	EBT	(6)	(6)	(9)	(9)	(11)	(9)	(9)	(13)	(8)	(16)
	EBT margin, %	(239.05)	(248.45)	(243.84)	(9,623.22)	(339.76)	0.00	0.00	0.00	0.00	0.00
	Net income	(6)	(6)	(9)	(9)	(11)	(9)	(9)	(13)	(8)	(16)
	Depreciation	0	0	0	0	0	0	0	0	0	0
Per share, $
Per share, $	Revenue	2.67	2.90	3.53	0.06	1.19	0.00	0.00	0.00	0.00	0.00
	Earnings	(6.40)	(7.00)	(8.40)	(6.24)	(4.04)	(2.32)	(2.31)	(2.02)	(0.74)	(0.91)
	Cash flow	(4.97)	(5.44)	(9.72)	(4.25)	(4.58)	(2.23)	(3.33)	(1.36)	(0.70)	(0.87)
	Capex	(0.02)	(0.05)	0.00	(0.01)	0.00	(0.02)	0.00	0.00	0.00	0.00
	Free cash flow	(4.99)	(5.49)	(9.73)	(4.25)	(4.58)	(2.25)	(3.33)	(1.36)	(0.70)	(0.87)
	Book value	20.07	14.01	11.54	3.22	8.05	6.42	3.80	1.49	2.58	1.65
	Shares, m	1	1	1	1	3	4	4	6	11	18
Valuation, ×
Valuation, ×	P/E	0.00	0.00	0.00	0.00	0.00	—	—	—	—	—
	P/S	0.00	0.00	0.00	0.00	0.00	—	—	—	—	—
	P/B	0.00	0.00	0.00	0.00	0.00	—	—	—	—	—
	EV/Sales	0.00	0.00	0.00	0.00	0.00	—	—	—	—	—
	EV/FCF	1.06	1.10	0.49	0.31	1.73	—	—	—	—	—
Cash, $m
Cash, $m	Operating cash flow	(4)	(5)	(10)	(6)	(13)	(9)	(13)	(8)	(7)	(15)
	Capex	0	0	0	0	0	0	0	0	—	—
	Free cash flow	(4)	(5)	(10)	(6)	(13)	(9)	(13)	(8)	(7)	(15)
Balance, $m
Balance, $m	Working capital	18	12	12	5	23	26	15	9	27	29
	Total debt	—	—	—	0	0	0	0	—	—	—
	Net debt	(16)	(12)	(10)	(6)	(21)	(25)	(11)	(8)	(21)	(25)
	Shareholders’ equity	18	12	12	5	23	26	15	9	27	29
Returns, %
Returns, %	ROA	(26.06)	(38.17)	(61.37)	(86.50)	(72.06)	(33.83)	(38.41)	(80.92)	(37.10)	(52.04)
	ROIC	(229.92)	(574.31)	(358.62)	0.00	(396.76)	(1,656.09)	(154.05)	(1,248.22)	(135.49)	(327.72)
	ROE	(27.93)	(42.26)	(72.60)	(108.60)	(82.99)	(38.44)	(45.24)	(102.77)	(43.10)	(56.26)

Negative figures in brackets.

All 10 years →

Fiscal years to Jun 2021

Charts ten years each

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
GOSS Gossamer Bio, Inc.	$54.3M	— (loss-making)	— (loss-making)	−19.59% (below 0%: shrinking)	n/m	+16.32% (above 0%: growing)	100.00%	(282.25%)	Compare
RNTX Rein Therapeutics Inc.	$54.2M	— (loss-making)	—	—	n/m	−34.62% (below 0%: shrinking)	0.00%	0.00%	Compare
RNXT RenovoRx, Inc.	$53.7M	— (loss-making)	— (loss-making)	+115.40% (above 0%: growing)	n/m	−27.63% (below 0%: shrinking)	84.27%	(368.43%)	Compare
BOLD Boundless Bio, Inc.	$53.5M	— (loss-making)	—	—	n/m	−76.90% (below 0%: shrinking)	—	0.00%	Compare
ATHE Alterity Therapeutics Limited - Sponsored ADR	$52.0M	— (loss-making)	—	—	0.00%	−84.83% (below 0%: shrinking)	0.00%	—
INKT MiNK Therapeutics, Inc.	$50.7M	— (loss-making)	—	—	n/m	−32.73% (below 0%: shrinking)	0.00%	0.00%	Compare
LONA LeonaBio, Inc.	$49.8M	— (loss-making)	—	—	n/m	−142.29% (below 0%: shrinking)	0.00%	0.00%	Compare
CRBU Caribou Biosciences, Inc.	$49.8M	— (loss-making)	— (loss-making)	−43.79% (below 0%: shrinking)	n/m	−33.16% (below 0%: shrinking)	100.00%	(1,690.39%)	Compare
MREO Mereo BioPharma Group plc - Sponsored ADR	$49.3M	— (loss-making)	— (loss-making)	—	n/m	+21.02% (above 0%: growing)	0.00%	0.00%	Compare
Median of peers	$52.1M	—	—	−19.59%	—	−32.94%	0.00%	0.00%

All 614 Biotechnology stocks →